Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1
The DOI matches its Crossref record.
Abstract
OBJECTIVE: As circulating chromogranin A (CgA) has been claimed to be the best general neuroendocrine marker so far available, we evaluated the usefulness of CgA determination in the clinical assessment of patients with sporadic gastro-entero-pancreatic neuroendocrine tumors (GEP NETs) or multiple endocrine neoplasia type 1 (MEN 1). DESIGN AND METHODS: Plasma CgA levels were measured using a commercial enzyme-linked immunosorbent assay in 61 patients with sporadic GEP NET and in 25 with MEN 1 including 16 with GEP NET. Controls were 50 healthy volunteers, 46 patients with pituitary adenoma and 35 patients with primary hyperparathyroidism. RESULTS: The cutoff value for CgA established in our healthy subjects (as mean+2 s.d.) was 20 U/l. CgA levels were above the normal range in 71/77 patients with sporadic or MEN 1-related GEP NETs (92%), in four out of nine MEN 1 patients without GEP NETs (44%), and only in 22/81 control patients with pituitary or parathyroid disease (27%). Furthermore, CgA levels of over 100 U/l occurred in 36/77 patients with GEP NETs (47%) and only in one patient with a non-functioning pituitary adenoma. In the patients with GEP NETs, both tumor burden and secretory activity affected CgA levels, and successful surgical resection was associated with markedly decreased CgA values. CONCLUSIONS: Plasma CgA was confirmed to be a reliable marker for GEP NETs. Moreover, in MEN 1 patients the finding of very high CgA levels strongly suggests the presence of a GEP NET, as both primary hyperparathyroidism and pituitary adenomas rarely cause marked CgA increases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Jensen, R. T., Berna, M. J., Bingham, D. B., & Norton, J. A. (2008) · Cancer · doi:10.1002/cncr.23648 · Cited by 488
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
The Extended Granin Family: Structure, Function, and Biomedical Implications
Bartolomucci, A., Possenti, R., Mahata, S. K., Fischer-Colbrie, R., Loh, Y. P., & Salton, S. R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0027 · Cited by 348
Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana, D., Nori, F., Piscitelli, L., Morselli-Labate, A. M., Pezzilli, R., Corinaldesi, R., & Tomassetti, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1535 · Cited by 248
“These findings are in agreement with others reported in the literature, where a variable cutoff value from 17 to 34 U/L was identified, with a variable specificity (83% to 91%)(13,17-19) and sensitivity (79% to 92%).(7,13,17-19) In our series, the higher specificity obtained was a result of the careful selection of HP…”
InfluentialBerna, M. J., Hoffmann, K. M., Serrano, J., Gibril, F., & Jensen, R. T. (2006) · Medicine · doi:10.1097/01.md.0000236956.74128.76 · Cited by 221
Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours
Nehar, D., Lombard‐Bohas, C., Olivieri, S., Claustrat, B., Chayvialle, J., Penes, M., Sassolas, G., & Borson‐Chazot, F. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02030.x · Cited by 177
“First, we measured the day-to-day variation of CgA and found it lower than that previously obtained in gastrinoma (AbouSaif et al., 2003) but comparable to that reported recently in a similar group of GEP-ET (Peracchi et al., 2003).”
MethodResultInfluentialNeuroendocrine tumors of the gastro-entero-pancreatic system.
Massironi, S., Sciola, V., Peracchi, M., Ciafardini, C., Spampatti, M. P., & Conte, D. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.5377 · Cited by 177
Self-citationMarotta, V., Zatelli, M. C., Sciammarella, C., Ambrosio, M. R., Bondanelli, M., Colao, A., & Faggiano, A. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0269 · Cited by 161
Nikou, G. C., Marinou, K., Thomakos, P., Papageorgiou, D., Sanzanidis, V., Nikolaou, P., Kosmidis, C., Moulakakis, A., & Mallas, E. (2008) · Pancreatology · doi:10.1159/000152000 · Cited by 84
Metadata
- Authors
- Peracchi, M., Conte, D., Gebbia, C., Penati, C., Pizzinelli, S., Arosio, M., Corbetta, S., & Spada, A.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-01-01
- Volume
- 148
- Issue
- 1
- Pages
- 39-43
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2145770998
- Cited by
- 75
- References
- 0
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.